Corning Asahi Video Products Co. (CAV) has reached an agreement to sell certain manufacturing assets from the company's facility in State College, Pa., to the Henan Anyang CPT Glass Bulb Group, Xinyi Electronic Glass Co. Ltd., in Henan Province, China. Terms of the sale were not disclosed. On April 15, Corning Inc. announced that CAV, a partnership between Corning and Asahi Glass America (a wholly owned subsidiary of Asahi Glass Co. Ltd. of Tokyon) had experienced a rapid deterioration of demand for its products and would discontinue its business operations. . . . Tactex Controls Inc., a developer of patented fiber optic-based Kinotex products, has been awarded a contract to develop a manufacturing line for Nitta Corp. The line will be based on the current Tactex manufacturing line, with modifications for the prototyping and manufacture of bed sensors and "digital skins" used for humanoid robots now under development in Japan. The hardware will be shipped to Japan late in 2003. Nitta acquired a license to Kinotex for use in the Asian market in 2002. The new line will allow Nitta to manufacture products developed by Tactex and to develop new products. Under the terms of the license, Tactex has the right to commercialize new products, such as the robotic sensors, outside the Asian market. . . . Case Western Reserve University (CWRU) has completed a technology license agreement with Interventional Imaging Inc. (I3), a medical device company developing technology to prevent heart attacks through the detection and treatment of plaque in the coronary arteries. I3 was formed by professors Jonathan Lewin and Jeffrey Duerk of the Department of Radiology in CWRU's School of Medicine and University Hospitals of Cleveland with the assistance of CWRU's Office of Technology Transfer, based on technologies the professors developed over four years of research. The technology consists of small magnetic resonance imaging coil catheters with related software that are used to obtain high-resolution images of the coronary arteries and to treat atherosclerotic plaques that have a high risk of rupturing and causing heart attack or stroke.